case,ID,colrev_origin,ENTRYTYPE,author,year,title,volume,number,pages,abstract,doi,isbn,url,colrev_status,container_title,author_full
source_1.bib/0000001610;source_1.bib/0000000599,1610,source_1.bib/0000001610,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,1,,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jregpep201205039,0167-0115,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=70929072 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed13&rft.genre=article&rft_id=info:doi/10.1016%2Fj.appet.2012.05.003&rft_id=info:pmid/&rft.issn=0195-6663&rft.volume=59&rft.issue=SUPPL.+1&rft.spage=e24&rft.pages=e24&rft.date=2012&rft.jtitle=Appetite&rft.atitle=Liraglutide+and+linagliptin+improves+glycemic+control+but+show+differential+anti-obesity+and+hypolipidemic+efficacy+in+a+novel+hamster+model+of+diet-induced+obesity+and+hypercholesterolemia&rft.aulast=Hansen&rft.isbn=,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001610;source_1.bib/0000000599,599,source_1.bib/0000000599,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,1,,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jappet201205003,0195-6663,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=70929072http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed13&rft.genre=article&rft_id=info:doi/10.1016%2Fj.appet.2012.05.003&rft_id=info:pmid/&rft.issn=0195-6663&rft.volume=59&rft.issue=SUPPL.+1&rft.spage=e24&rft.pages=e24&rft.date=2012&rft.jtitle=Appetite&rft.atitle=Liraglutide+and+linagliptin+improves+glycemic+control+but+show+differential+anti-obesity+and+hypolipidemic+efficacy+in+a+novel+hamster+model+of+diet-induced+obesity+and+hypercholesterolemia&rft.aulast=Hansen&rft.isbn=,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001610;source_1.bib/0000001347,1347,source_1.bib/0000001347,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,59,1,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jappet201205003,0195-6663,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed13&NEWS=N&AN=70929072,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001610;source_1.bib/0000001347,1610,source_1.bib/0000001610,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,1,,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jregpep201205039,0167-0115,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=70929072 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed13&rft.genre=article&rft_id=info:doi/10.1016%2Fj.appet.2012.05.003&rft_id=info:pmid/&rft.issn=0195-6663&rft.volume=59&rft.issue=SUPPL.+1&rft.spage=e24&rft.pages=e24&rft.date=2012&rft.jtitle=Appetite&rft.atitle=Liraglutide+and+linagliptin+improves+glycemic+control+but+show+differential+anti-obesity+and+hypolipidemic+efficacy+in+a+novel+hamster+model+of+diet-induced+obesity+and+hypercholesterolemia&rft.aulast=Hansen&rft.isbn=,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001782;source_1.bib/0000000599,1782,source_1.bib/0000001782,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,1,,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jregpep201205039,0167-0115,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=70929072 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed13&rft.genre=article&rft_id=info:doi/10.1016%2Fj.appet.2012.05.003&rft_id=info:pmid/&rft.issn=0195-6663&rft.volume=59&rft.issue=SUPPL.+1&rft.spage=e24&rft.pages=e24&rft.date=2012&rft.jtitle=Appetite&rft.atitle=Liraglutide+and+linagliptin+improves+glycemic+control+but+show+differential+anti-obesity+and+hypolipidemic+efficacy+in+a+novel+hamster+model+of+diet-induced+obesity+and+hypercholesterolemia&rft.aulast=Hansen&rft.isbn=,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001782;source_1.bib/0000000599,599,source_1.bib/0000000599,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,1,,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jappet201205003,0195-6663,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=70929072http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed13&rft.genre=article&rft_id=info:doi/10.1016%2Fj.appet.2012.05.003&rft_id=info:pmid/&rft.issn=0195-6663&rft.volume=59&rft.issue=SUPPL.+1&rft.spage=e24&rft.pages=e24&rft.date=2012&rft.jtitle=Appetite&rft.atitle=Liraglutide+and+linagliptin+improves+glycemic+control+but+show+differential+anti-obesity+and+hypolipidemic+efficacy+in+a+novel+hamster+model+of+diet-induced+obesity+and+hypercholesterolemia&rft.aulast=Hansen&rft.isbn=,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001782;source_1.bib/0000001347,1347,source_1.bib/0000001347,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,59,1,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jappet201205003,0195-6663,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed13&NEWS=N&AN=70929072,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
source_1.bib/0000001782;source_1.bib/0000001347,1782,source_1.bib/0000001782,article,hansen hansen pedersen jelsing vrang hansen,2012,liraglutide linagliptin improves glycemic control but show differential anti obesity hypolipidemic efficacy novel hamster model diet induced obesity hypercholesterolemia,1,,24,unlike mice and rats golden syrian hamsters fed a highfat diet with cholesterol supplementation quickly develop hyperlipidemia and hypercholesterolemia thus showing closer similarity to human lipoprotein metabolism. we developed a novel hamster model of dietinduced obesity dio and evaluated the efficacy of the glp1 analog liraglutide and dppiv inhibitor linagliptin. hamsters fed a high fathigh carbohydrate diet with cholesterol supplementation for 12 weeks developed an obese phenotype with impaired oral glucose tolerance and significantly elevated insulin triglyceride total cholesterol ldl and hdl cholesterol levels. pancreatic and atherogenetic markers are currently being evaluated. chronic treatment with liraglutide 0.2 mgkg b.i.d s.c. 4 weeks normalized body weight with a complete reversal of wholebody fat mass gain. liraglutide also reduced plasma triglyceride and cholesterol levels. both liraglutide and linagliptin 3.0 mgkg q.d. p.o. normalized glucose tolerance. in conclusion liraglutide and linagliptin both improved glycemic control. liraglutide also showed robust antiobesity and cholesterollowering effects in the dio hamster supporting the view that chronic glp1 receptor agonism may also lower cholesterolassociated cardiovascular risk factors in diabetes and obesity. this dio hamster model is particularly useful for evaluation of novel antiobesity lipid modulating and insulin sensitizing agents,101016/jregpep201205039,0167-0115,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed13&AN=70929072 http://ru.on.worldcat.org/atoztitles/link?/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed13&rft.genre=article&rft_id=info:doi/10.1016%2Fj.appet.2012.05.003&rft_id=info:pmid/&rft.issn=0195-6663&rft.volume=59&rft.issue=SUPPL.+1&rft.spage=e24&rft.pages=e24&rft.date=2012&rft.jtitle=Appetite&rft.atitle=Liraglutide+and+linagliptin+improves+glycemic+control+but+show+differential+anti-obesity+and+hypolipidemic+efficacy+in+a+novel+hamster+model+of+diet-induced+obesity+and+hypercholesterolemia&rft.aulast=Hansen&rft.isbn=,md_processed,appe,Hansen F.Hansen G.Pedersen P. J.Jelsing J.Vrang N.Hansen H. B.
